# Carisma Therapeutics Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Carisma Therapeutics Inc.). ## Overview Carisma Therapeutics Inc. is a U.S.-based biotechnology company that was built around macrophage engineering for serious diseases such as liver fibrosis and cancer. In its recent filings, the company says it has ceased further development of its lead programs CT-0508 and CT-0525 and does not intend to resume its historical research and development activities. Instead, Carisma is focused on preserving cash, monetizing remaining assets, and pursuing an orderly wind down of operations. The company also has a material strategic transaction context, including the planned OrthoCellix merger described in its 2025 filings. ## Products & services • Macrophage-engineered cell therapy research • CT-0508 anti-HER2 product candidate • CT-0525 product candidate • Preclinical drug discovery and development • Manufacturing process development for cell therapies • Strategic collaboration and licensing arrangements - **Cell therapy product candidates** (0%) — Experimental macrophage-engineered therapies and related programs intended for serious diseases such as cancer and liver fibrosis. - **Research and development services** (0%) — Internal discovery, preclinical work, and early-stage clinical development activities supporting pipeline advancement. - **Collaboration and licensing revenue** (100%) — Revenue recognized from partner arrangements, including the Moderna collaboration and related license accounting. - **Asset monetization and wind-down activities** (0%) — Disposition of remaining assets and other non-core activities as the company exits historical operations. - Macrophage-engineered cell therapy research - CT-0508 anti-HER2 product candidate - CT-0525 product candidate - Preclinical drug discovery and development - Manufacturing process development for cell therapies - Strategic collaboration and licensing arrangements ## Customers Carisma does not currently sell commercial products, so it does not have a traditional customer base for approved therapies. Its historical counterparties were collaboration partners such as Moderna and other potential licensing or strategic partners that could fund development or provide access to technology. If any future value is realized, it would likely come from pharmaceutical or biotech partners acquiring rights to assets, technologies, or product candidates rather than from direct product sales. The company’s recent filings also indicate it is seeking to monetize remaining assets during an orderly wind down, which shifts the relevant 'customer' set toward acquirers, licensees, and merger counterparties. - **Strategic collaboration partners** (primary) — Pharmaceutical or biotech partners that enter research, option, or license agreements to access Carisma's macrophage engineering platform and share development risk. - **Licensees and asset buyers** (primary) — Companies that may acquire remaining intellectual property, product candidates, or platform rights as Carisma winds down operations. - **Merger and financing counterparties** (primary) — Investors and transaction partners involved in the OrthoCellix merger and related financing, which are central to the company's near-term corporate strategy. - **Future healthcare end users** (emerging) — Patients, physicians, and payors would only become relevant if a product candidate were successfully developed and approved, which the company does not currently expect to resume. - Biopharma collaboration partners that fund or co-develop platform assets - Licensees seeking rights to macrophage engineering technology - Strategic acquirers of remaining pipeline or IP assets - Merger counterparties and investors in recapitalization transactions - Potential future patients and payors only if a product is ever approved ## Geography Carisma is headquartered in the United States and its filings are presented as those of a U.S. issuer. The company does not disclose meaningful country-by-country revenue because it has not commercialized products and has not generated product sales. Its business activity has been centered on U.S.-based corporate, research, and development functions, with strategic and financing activity also tied to U.S. capital markets. Geography matters mainly through access to U.S. biotech funding, regulatory oversight, and the location of its remaining operations and counterparties. - United States is the company's home market and operating base - No disclosed product-sales geography because the company has not commercialized products - U.S. capital markets are central to financing and merger activity - Regulatory and development activity has been tied to U.S. biotech oversight - No authoritative country revenue breakdown is available from the excerpts ## Strategy Carisma's stated strategy has shifted away from building a commercial cell therapy company toward conserving cash and winding down operations. In March and December 2024, management approved revised operating plans to reduce monthly expenses and refocus priorities, including stopping further development of CT-0508 and later CT-0525. The company says it has no intention of resuming historical R&D and instead expects to sell or otherwise monetize remaining assets. Near-term strategic value is therefore tied to transaction execution, asset disposition, and preserving optionality rather than pipeline expansion. - **Cash preservation and operating reduction** (short-term) — The company has very limited cash and has explicitly reduced operations to extend runway while it evaluates strategic alternatives. - **Asset monetization and wind-down execution** (short-term) — Management states it will not resume historical R&D and instead aims to sell or otherwise monetize remaining assets in an orderly manner. - **Transaction completion and capital structure resolution** (short-term) — The OrthoCellix merger and related financing are central to the company's current strategic path and ownership structure. - Reduce monthly operating expenses and preserve cash - Stop further development of CT-0508 and CT-0525 - Monetize remaining assets through sale or disposition - Pursue an orderly wind down of remaining operations - Complete or otherwise resolve the OrthoCellix transaction path - Limit spending while maintaining compliance and corporate continuity ## Risks Carisma faces acute going-concern and liquidity risk because it has minimal cash, no commercial product revenue, and has shifted into wind-down mode. The company also highlights transaction risk around the OrthoCellix merger, including the possibility that the deal is not completed or does not deliver the expected strategic benefits. As a biotech company, it remains exposed to general industry risks such as clinical, regulatory, manufacturing, and intellectual property uncertainty, even though it has paused or ceased key development programs. Its stock price is also vulnerable to volatility, low trading volume, and litigation risk if investors react negatively to strategic transaction outcomes or capital-raising needs. - **Liquidity shortfall and wind-down uncertainty** [critical] — The company has only a small cash balance and states it is pursuing an orderly wind down, with no assurance of stockholder distributions. - **OrthoCellix merger failure or value dilution** [high] — The company says the merger may not close and that Carisma holders are expected to own only a small portion of the combined company if it does. - **Clinical and regulatory development risk** [high] — Biotech programs depend on preclinical and clinical success, regulatory review, and manufacturing scale-up, all of which are uncertain and costly. - **Stock price volatility and litigation risk** [medium] — Management notes low trading volume, broad market volatility, and the possibility of securities class actions after price declines. - Liquidity and going-concern pressure from very limited cash and no product revenue - Failure to complete the OrthoCellix merger or another strategic transaction - Wind-down risk, including uncertain timing and amount of any stockholder distributions - Biotech development risk from clinical, regulatory, and manufacturing uncertainty - Intellectual property and licensing risk around remaining assets and collaborations - Share price volatility and securities litigation risk due to low trading volume ## Accounting The most important accounting issue for Carisma is revenue recognition from collaboration arrangements, especially the Moderna upfront payment that was recognized through the amendment process and drove reported net income in 2025. Because the company has no product sales, reported revenue can be highly episodic and depend on contract amendments, deferred revenue balances, and the timing of recognition rather than operating demand. Investors should also watch estimates tied to wind-down activities, severance, contract termination costs, and any liabilities associated with strategic transactions or employee departures. As a development-stage biotech in wind-down mode, the company’s financial statements are also sensitive to judgments about asset recoverability, contingent obligations, and whether remaining assets can be monetized at carrying value. - **Collaboration revenue recognition** — Can create large non-operating earnings volatility - **Deferred revenue** — Impacts revenue timing and quarter-to-quarter comparability - **Wind-down and severance accruals** — Affects operating expenses and liability recognition - **Asset impairment and recoverability** — Could reduce asset values and increase losses - Collaboration revenue recognition can create large one-time earnings swings - Deferred revenue balances may be released when agreements are amended - No product sales means revenue is not recurring or demand-driven - Wind-down costs and severance require accrual estimates and judgment - Asset recoverability and monetization assumptions affect carrying values - Transaction-related costs can materially affect quarterly results --- *Last updated: 2026-04-28T14:25:55.158954+00:00*